EN
Human Apolipoprotein CII
Delipidated whole molecule
Product Overview, Sizes and Prices | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Proteins Synonyms: ApoCII, ApoC2 Source: Human Plasma Purity: ≥ 95% by SDS-PAGE Physical State: Lyophilized from 10 mM NH4HCO3, pH 7.4 Manufacturer: |
|
|||||||||||||
Athens Research & Technology
Produktdetails
Synonyms
ApoCII, ApoC2
Description of Human Apolipoprotein CII
Human Apolipoprotein CII is a 8.8 kDa protein. Apolipoprotein CII (ApoCII) is a 79-amino acid protein encoded by the APOC2 gene, serving as an essential cofactor for lipoprotein lipase (LPL) activation. This protein circulates in plasma as a component of triglyceride-rich lipoproteins (TRLs), including very low-density lipoproteins (VLDL) and chylomicrons, with normal concentrations ranging from 3–8 mg per 100 mL. ApoCII binds to LPL via its C-terminal α-helix (residues 58–79), stabilizing the enzyme’s catalytic domain and facilitating the hydrolysis of VLDL triglycerides into free fatty acids and glycerol, a process critical for generating intermediate-density lipoproteins (IDL). This lipolytic activity enables cellular energy uptake and regulates plasma lipid homeostasis. Deficiency in ApoCII, caused by biallelic APOC2 mutations, results in familial hyperlipoproteinemia type IB, characterized by severe hypertriglyceridemia (>1, 000 mg/dL), recurrent pancreatitis, and eruptive xanthomas. The absence of functional ApoCII impairs LPL-mediated triglyceride clearance, leading to chylomicronemia and atherosclerosis in preclinical models. Heterozygotes typically remain asymptomatic due to ApoCII’s excess physiological presence. Clinically, ApoCII deficiency is diagnosed through genetic testing and plasma apolipoprotein profiling, with acute pancreatitis managed via fresh frozen plasma infusions to replenish ApoCII. Emerging therapeutic strategies include synthetic ApoCII mimetic peptides, such as C-II-a, which combine lipid-binding and LPL-activating domains to restore triglyceride metabolism. While gene therapies like alipogene tiparvovec showed promise in preclinical studies, their clinical adoption remains limited. Additionally, ApoCII’s role in modulating lipoprotein particle interactions positions it as a biomarker for cardiovascular risk assessment and a target for lipid-lowering interventions.
Source
Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
Storage
For long term, store Human Apolipoprotein CII at -20°C.
Applications
In Vitro Diagnostics, Cardiovascular Research.
Citations/Publications
Deng, M. et al., (2018), 'LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration', Nature, 562: pp 605–609. Available at: https://doi.org/10.1038/s41586-018-0615-z
NCBI: https://www.ncbi.nlm.nih.gov/protein/P02655
Shipped with ice packs
Gel Scan of Human Apolipoprotein CII
| Fig. 1: SDS-PAGE Gel |
Usage: For research use only. Not for use in diagnostic or therapeutic procedures. Not for human use.
To buy Human Apolipoprotein CII please click on the Shopping List Symbol right from the indicated price. This will add Human Apolipoprotein CII to your Shopping List. You can then click on the button »Shopping List & Order Form« to ask for a quote. We will send you your quote as soon as possible. Our offer will include institutional discounts where applicable.
For business customers only. All prices are net prices (excluding VAT). Final prices in our quote will contain VAT plus shipping costs if applicable. For further information please go to our Shipping page.
Errors, changes and availability excepted.
Payment Methods
Paying by bank transfer
